Trials / Completed
CompletedNCT00876421
Study of ONO-8539 in Patients With Overactive Bladder
A Randomised, Multi-Centre, Double-Blind, Placebo and Active-Controlled, 5-Way Parallel Group Study to Investigate the Efficacy, Safety and Tolerability of ONO-8539 in Patients With Overactive Bladder
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 435 (actual)
- Sponsor
- Ono Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to investigate efficacy, safety and tolerability of ONO-8539 in patients with overactive bladder.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | Placebo / 12 weeks |
| DRUG | Tolterodine | 4mg / 12 weeks |
| DRUG | ONO-8539 | low dose / 12 weeks |
| DRUG | ONO-8539 | medium dose / 12 weeks |
| DRUG | ONO-8539 | higher dose / 12 weeks |
Timeline
- Start date
- 2009-04-01
- Primary completion
- 2010-04-01
- First posted
- 2009-04-06
- Last updated
- 2012-06-14
Locations
50 sites across 9 countries: Czechia, Germany, Hungary, Netherlands, Poland, Romania, Russia, Sweden, Ukraine
Source: ClinicalTrials.gov record NCT00876421. Inclusion in this directory is not an endorsement.